Tampa, Florida, United States – TheNewswire – September 10, 2025 – CTT Pharmaceuticals Holdings, Inc. (OTCQB:CTTH) is pleased to announce it has signed a contract for a $3 Million Equity Line of Credit. The funds from this line will be used for the manufacturing of CTT's patented technology. CTT will immediately move forward with a S-1 filing and will become a SEC reporting company. CTT will notify shareholders in greater detail once the Equity Line becomes available.

CTT Pharma has not been notified of an approval or denial from the NIH for clinical trials with Johns Hopkins University. CTT will notify shareholders once this information becomes available.

 

Additional Corporate Updates for CTT Pharma:  

• CTT’s submission to the National Science Foundation (NSF) Grant Program remains under review, with a funding decision anticipated towards the end of the fourth quarter. 

• The Small Business Association(SBA) is expected to notify CTT regarding potential approval for a loan, which if awarded, will be directed towards manufacturing.  

• Our scientists are finalizing a manuscript for submission to a peer-reviewed journal. We look forward to sharing the publication once peer review is complete and the manuscript has been accepted. 

• The PCAOB audit firm that CTT hired successfully completed an audit for 2024. CTT now has 3 years of PCAOB audits completed. 

  

CTT Pharma – 813-606-0060